BNTX BioNTech SE - ADR

$BNTX $MRNA “The smaller the float, the bigger the squeeze potential. Less supply, more explosive upside when demand hits!” 🔥

$BNTX has one of the strongest balance sheets in biotech, with substantial cash and liquid investments (>80% of its current market cap) and minimal debt. The market seems to be assigning very little value to its oncology pipeline. In my view, the ESMO 2026 results have been encouraging so far!

$BNTX Going to 80's. Leaderless until February. Their technology did not work and the best ideas are walking out the door with the CEO's and CMO's departure. Just a company wondering in the desert and all their supplies taken.

$BNTX Current $22B market cap for BNTX reminds me of how cheaply the market valued Moderna when it was trading below $30 not long ago.

$BNTX · $BMY 🏥 BioNTech SE and Bristol-Myers Squibb Company reported Phase 2 data for pumitamig plus docetaxel in advanced NSCLC after progression on immunotherapy plus chemotherapy, showing a confirmed objective response rate of 36.7% and median progression-free survival of 6.9 months. Prioritized by relevance

$BNTX Doesn’t go up when Moderna goes up, goes down when Moderna goes down. Likely will see $80 before it sees $100 here. Major updates on its pipeline won’t come for years hear and who knows how the market will look like then. I am lowering my expectations on this from $90 to $80 with sector risk if Moderna continues going down.

$BNTX Perhaps the biggest stock failure in the last 12 months. mRNA technology was so promising and BioNtech just squandered it all. Thankfully, I jettisoned this company early 2026 and went all in on Moderna. Any reason for a second look? Seems like dead money until new leadership takes the helm next year. Any catalysts between now and March of next year? They promised many positive surprises in 2026. 2026 was to be a great year . . .anyone?

$BNTX has inferior technology. mRNA was a moon shot; only $MRNA was successful. BioNTech is on a plane at full speed into the ground. Yes, there is hope in the future - but how long do you need to wait. The risk is that Moderna mRNA expertise increasingly pulls away from BNTX. Will continue to watch and when they have first breakthrough jump in or maybe reboard sometime next year if the cash burn is not too bad. A massive residual risk is the mRNA technology role - still unfilled? REALLY? Guido Oelkers looks like a great leader but has zero mRNA experience, not a mRNA scientific pioneer. Yikes. At this moment, BNTX is a no touch. Was fortunate and lucky to exit a bit before the CEO and CMO announced their departure. Do not expect anything good in the near term.

$BNTX no way for $AZN TO ENTER THE MRA MARKET UNLESS IT LICENSES IT FROM MODERNA OR BIONTECH. MOST LIKELY ASTRAZENECA WILL JUST BUY BIONTECH SINCE BIOTECH IS IN GERMANY AND ALSO EUROPEAN AND THEN IT GETS THE FULL FREEDOM TO ENTER THE MARKET. All caps for emphasis

$BNTX As stated, this will continue dropping with Moderna due to assymetric risk, especially when the pipeline is years out. I reiterate my $80 assumption.

$BNTX 🏥 BioNTech SE and DualityBiologics (Suzhou) Co., Ltd. reported topline Phase 3 DYNASTY-Breast02 results showing trastuzumab pamirtecan met the primary endpoint with a statistically significant but modest progression-free survival improvement versus chemotherapy in chemotherapy-naïve HR+/HER2-low metastatic breast cancer; overall survival data were immature and interstitial lung disease rates were higher. Curated for market relevance

$BNTX Soon, BNTX’s MC will surpass MRNA’s, as more and more details come out of the respective pipeline. JMO

$BNTX Disappointments mostly built in the current pathetic stock price. Will hold steady until BNT 327, 323, and 316 are proven fully successful. JMO

$BNTX Fake companies like moderna up 250 % + the past few months & novavax up But bntx stuck on stupid

$BNTX Follow-up: German drugmaker BioNTech's HER2 drug beat chemo in breast cancer only modestly. 🏢 BioNTech is a Mainz-based cancer drug developer worth about $22.28B at $88.115 a share at 16:00 ET on October 23, 2026, with €7.68B of cash and cash equivalents as of December 31, 2025 📉 The companies say the benefit would be limited in HR+/HER2-low metastatic breast cancer, and lung inflammation (ILD) was more frequent than in earlier trials, with a small share of severe or fatal cases ✅ On the other side, the trial did meet its primary endpoint, and the drug is still in a second Phase 3 trial in HER2-expressing endometrial cancer and a Phase 1/2 solid-tumor trial, among the 13 Phase 3 trials BioNTech says it is running 📅 Next: BioNTech and DualityBio say they will discuss the data and decide next steps; no date given Source: SEC 6-K, Oct 26 + SEC 6-Ks, Oct 13 and Oct 19

$BNTX This company is developing something similar to what you $BNTX are working on—a melanoma cancer vaccine. It's still really undervalued, and the data released yesterday looks very promising and highly competitive. Let's get rich together!! Buy some shares while it's still cheap!

$BNTX looking to add my way to a thousand shares by end of next year. Some discounts along the way shall help. So I appreciate the shorts.

$BNTX treating late stage unresectable is always hard vs early stage (eg Moderna ) so this is the likely scenario Pumitamig and gotistobart still in play

BioNTech’s Cancer Drug Misses A Key Trial Goal – Citi Says Survival Data Could Preserve ‘A Meaningful Development Path’ $BNTX $XBI https://stocktwits.com/news/equity/markets/bio-n-tech-s-cancer-drug-misses-a-key-trial-goal-citi-says-survival-data-could-preserve-a-meaningful-development-path/cZxBViFRBYa

$BNTX 🏥 BioNTech SE reported that its Phase 2/3 AHEAD-MERIT trial of BNT113 plus pembrolizumab did not meet the first dual primary endpoint of progression-free survival in metastatic HPV16-positive head and neck cancer, while the trial continues to evaluate overall survival.